HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Andreas Engert Selected Research

Etoposide (VP 16)

6/2021PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial.
4/2021Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14).
11/2018Outcome-based interpretation of early interim PET in advanced-stage Hodgkin lymphoma.
12/2017PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group.
12/2017Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group.
1/2017Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma.
1/2017Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group.
1/2014Significant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DSHNHL.
9/2013Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis.
8/2013Treatment-related mortality in patients with advanced-stage hodgkin lymphoma: an analysis of the german hodgkin study group.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Andreas Engert Research Topics

Disease

151Hodgkin Disease (Hodgkin's Disease)
10/2022 - 01/2002
75Neoplasms (Cancer)
01/2022 - 01/2002
37Lymphoma (Lymphomas)
06/2022 - 01/2002
19Non-Hodgkin Lymphoma (Lymphosarcoma)
01/2021 - 06/2002
16Infections
08/2022 - 01/2002
9Anemia
01/2016 - 01/2005
7Febrile Neutropenia
12/2015 - 08/2003
7Multiple Myeloma
10/2015 - 03/2006
6Residual Neoplasm
10/2021 - 07/2005
6B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
02/2009 - 11/2002
5Fever (Fevers)
01/2021 - 11/2002
5Neutropenia
10/2018 - 08/2003
5Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular)
01/2017 - 03/2006
5Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma)
10/2016 - 11/2003
4Fatigue
12/2018 - 05/2010
4Disease Progression
10/2018 - 12/2010
4Myelodysplastic Syndromes (Myelodysplastic Syndrome)
10/2017 - 03/2014
4Pathologic Complete Response
12/2011 - 03/2006
3Hematologic Neoplasms (Hematological Malignancy)
02/2019 - 07/2012
3Breast Neoplasms (Breast Cancer)
12/2015 - 04/2003
3Carcinoma (Carcinomatosis)
06/2014 - 04/2003
3Infertility (Sterility)
01/2008 - 07/2005
2Second Primary Neoplasms (Neoplasms, Second)
01/2020 - 01/2017
2Exanthema (Rash)
12/2018 - 09/2016
2Sclerosis
12/2017 - 06/2007
2Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
10/2017 - 03/2014
2Long Term Adverse Effects
01/2017 - 02/2011
2Small Cell Lung Carcinoma (Small Cell Lung Cancer)
12/2015 - 05/2006
2Thrombocytopenia (Thrombopenia)
12/2015 - 11/2002
2Nausea
04/2015 - 02/2011
2Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome)
06/2009 - 09/2004
2B-Cell Lymphoma (Lymphoma, B Cell)
06/2008 - 06/2004

Drug/Important Bio-Agent (IBA)

32Doxorubicin (Adriamycin)FDA LinkGeneric
11/2021 - 01/2002
27Bleomycin (Blenoxane)FDA LinkGeneric
11/2021 - 01/2002
25Cyclophosphamide (Cytoxan)FDA LinkGeneric
06/2021 - 01/2002
24Prednisone (Sone)FDA LinkGeneric
06/2021 - 01/2002
23Vincristine (Oncovin)FDA LinkGeneric
06/2021 - 01/2002
20Procarbazine (Matulane)FDA Link
06/2021 - 01/2002
19Etoposide (VP 16)FDA LinkGeneric
06/2021 - 01/2002
17Rituximab (Mabthera)FDA Link
01/2020 - 11/2002
15Brentuximab VedotinIBA
01/2022 - 06/2012
15Monoclonal AntibodiesIBA
12/2018 - 01/2003
14Dacarbazine (DIC)FDA LinkGeneric
11/2021 - 01/2002
14Vinblastine (Vinblastine Sulfate)FDA Link
11/2021 - 01/2002
11Granulocyte Colony-Stimulating Factor (G-CSF)IBA
02/2016 - 08/2003
10Pharmaceutical PreparationsIBA
10/2019 - 08/2003
9AntibodiesIBA
01/2022 - 04/2003
8NivolumabIBA
01/2021 - 09/2016
8LigandsIBA
12/2018 - 03/2006
7Methotrexate (Mexate)FDA LinkGeneric
12/2020 - 01/2002
6Proteins (Proteins, Gene)FDA Link
01/2022 - 03/2006
6Anti-Bacterial Agents (Antibiotics)IBA
01/2021 - 05/2006
6ErythropoietinFDA Link
12/2012 - 01/2005
5Dexamethasone (Maxidex)FDA LinkGeneric
01/2022 - 12/2005
5AntigensIBA
01/2022 - 04/2003
5Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA
02/2016 - 08/2003
4Immune Checkpoint InhibitorsIBA
09/2017 - 01/2016
4PanobinostatIBA
01/2017 - 06/2012
4HematinicsIBA
02/2016 - 12/2008
4Colony-Stimulating Factors (Colony Stimulating Factor)IBA
02/2016 - 01/2009
4Alemtuzumab (Campath)FDA Link
02/2012 - 10/2005
4GemcitabineFDA Link
12/2011 - 06/2004
3Biomarkers (Surrogate Marker)IBA
01/2021 - 04/2009
3Cytarabine (Cytosar-U)FDA LinkGeneric
12/2020 - 02/2010
3Immunoconjugates (Immunoconjugate)IBA
12/2017 - 07/2014
3CytokinesIBA
12/2014 - 01/2013
3pixantrone (BBR 2778)IBA
04/2011 - 08/2003
3Antineoplastic Agents (Antineoplastics)IBA
07/2009 - 01/2005
3Biological ProductsIBA
06/2009 - 10/2007
3fludarabineIBA
01/2009 - 11/2002
3Hemoglobins (Hemoglobin)IBA
04/2005 - 01/2005
2Cell-Free Nucleic AcidsIBA
10/2021 - 09/2017
2Vitamin DFDA LinkGeneric
12/2019 - 11/2017
2Histone Deacetylase InhibitorsIBA
02/2019 - 01/2013
2EnzymesIBA
02/2019 - 04/2003
2Lenalidomide (CC 5013)FDA Link
01/2019 - 02/2010
2Lipase (Acid Lipase)FDA Link
10/2018 - 09/2016
2pembrolizumabIBA
01/2017 - 01/2017
2ChemokinesIBA
05/2014 - 06/2009
2Cetuximab (Erbitux)FDA Link
03/2014 - 03/2010
2Natural Killer Cell ReceptorsIBA
04/2013 - 08/2009
2Interleukin-10 (Interleukin 10)IBA
01/2013 - 11/2008
2Epoetin Alfa (Epogen)FDA Link
05/2010 - 05/2006
2NF-kappa B (NF-kB)IBA
08/2009 - 09/2005
2Adrenal Cortex Hormones (Corticosteroids)IBA
07/2008 - 06/2004
2PlasticsIBA
05/2008 - 04/2003

Therapy/Procedure

80Drug Therapy (Chemotherapy)
08/2022 - 01/2002
48Radiotherapy
11/2021 - 01/2002
42Therapeutics
01/2022 - 01/2002
19Stem Cell Transplantation
09/2016 - 12/2005
14Immunotherapy
01/2017 - 03/2002
7Erythrocyte Transfusion
02/2016 - 01/2005
6Aftercare (After-Treatment)
10/2021 - 01/2008
6Combination Drug Therapy (Combination Chemotherapy)
12/2017 - 06/2004
2Combined Modality Therapy
11/2021 - 01/2002
2Induction Chemotherapy
05/2016 - 12/2005
2Blood Transfusion (Blood Transfusions)
02/2016 - 04/2005
2Transplantation
10/2015 - 08/2005
2Autologous Transplantation
10/2015 - 09/2011
2Chemoradiotherapy
01/2009 - 07/2004